Enter your login e-mail to the account
Search
- Systemic lupus erythematosus – an overview of new knowledge in pathogenesis, clinical picture and treatment
doc. Ing. Stanislava Blažíčková, PhD., prof. MUDr. Jozef Rovenský, DrSc., FRPC, MUDr. Ivana Stiborová
(2/2012, Review articles ) - The first symptoms of multiple sclerosis and the importance of early treatment
Doc. MUDr. Vladimír Donáth, PhD.
(5/2017, Interdisciplinary consilium ) - Multiple sclerosis – maternity and breastfeeding
MUDr. Olga Zapletalová
(6/2019, Interdisciplinary consilium )
- New drugs era in treating multiple sclerosis
MUDr. Marta Vachová
(5/2009, Review articles ) - Ocrelizumab – clinical evaluation and disease progression – 6,5 years data
MUDr. Eva Recmanová
(5/2021, Review articles ) - Management of secondary-progressive multiple sclerosis
MUDr. Martin Elišák, Ph.D.
(1/2022, Review articles ) - The initial results and our experiences from the OCARINA II study indicate that the subcutaneous form of ocrelizumab is comparable in efficacy to the intravenous form
MUDr. Michal Dufek, Ph.D.
(5/2024, Case reports ) - Safety monitoring of escalation treatment of multiple sclerosis
MUDr. Jiří Piťha
(5/2019, Review articles ) - Experience with shortened ocrelizumab infusion – ENSEMBLE PLUS study
doc. MUDr. Yvonne Benešová, Ph.D.
(1/2022, Review articles ) - Multiple sclerosis: adherence to treatment
MUDr. Zbyšek Pavelek, Ph.D., MUDr. Simona Halúsková, MUDr. Jana Šarláková, prof. MUDr. Martin Vališ, Ph.D., FEAN
(5/2020, Review articles ) - Anti CD20 multiple sclerosis therapy
Doc. MUDr. Pavel Štourač, Ph.D.
(1/2018, Pharmacotherapy ) - Early highefficacy mulitple sclerosis treatment: therapeutic success despite safety barriers
MUDr. Dominika Šťastná, Ph.D., prof. MUDr. Manuela Vaněčková, Ph.D., doc. MUDr. Dana Horáková, Ph.D.
(6/2023, Case reports ) - Efficacy and safety of ocrelizumab in multiple sclerosis
MUDr. Radek Ampapa
(5/2017, Review articles ) - Long term efficacy of ocrelizumab on MRI parameters in multiple sclerosis patients
MUDr. Pavel Hradílek, Ph.D.
(1/2020, Review articles ) - The use of monoclonal antibodies in neurology
prof. MUDr. Egon Kurča, PhD., MUDr. Mária Cuninková
(6/2011, Main topic ) - Ocrelizumab since the first multiple sclerosis attack – a milestone in reimbursement criteria
MUDr. Dominika Šťastná, MUDr. Ingrid Menkyová, doc. MUDr. Dana Horáková, Ph.D.
(4/2022, Review articles ) - Pharmacotherapy of multiple sclerosis in light of the necessary costs associated with prescribing the indicated drug
MUDr. Jiří Slíva, Ph.D.
(4/2018, From the boundary of neurology ) - Multiple sclerosis: treatment, monitoring, activity and disability
MUDr. Zbyšek Pavelek, doc. MUDr. Martin Vališ, Ph.D.
(4/2018, Review articles ) - Porovnanie bezpečnosti a monitoringu DMD liekov prvej eskalačnej línie – dimetylfumarát, fingolimod, kladribin a okrelizumab
MUDr. Eva Kmeťová
(6/2018, Review articles ) - High efficacy treatment since the first attack – an important step in the treatment of multiple sclerosis?
MUDr. Dominika Šťastná, MUDr. Ingrid Menkyová, doc. MUDr. Dana Horáková, Ph.D.
(1/2023, Review articles ) - Immunological outlook on modern therapy of multiple sclerosis
doc. MUDr. Vojtěch Thon, Ph.D.
(5/2016, From the boundary of neurology ) - Improved cognitive function and employment in patients with relapsing multiple sclerosis treated with ocrelizumab
MUDr. Marek Peterka
(4/2023, Review articles ) - Safety aspects of treating relapsing-remitting multiple sclerosis
MUDr. Radek Ampapa, MUDr. Stanislav Kopecký
(5/2016, Review articles ) - Adherence to treatment in multiple sclerosis: case reports of three female patients on high-efficacy therapy with ocrelizumab
MUDr. Jana Pavlíčková, Ph.D.
(3/2024, Case reports ) - Novel treatment for myasthenia gravis
MUDr. Michaela Týblová, Ph.D.
(4/2023, Review articles ) - The role of B lymphocytes in the immunopathogenesis and treatment of multiple sclerosis
prof. MUDr. Ľubomír Lisý, DrSc.
(3/2024, Informations ) - Ocrelizumab – pharmacoloical profile
doc. MUDr. Radomír Taláb, CSc., MUDr. Marika Talábová
(5/2018, Pharmacotherapy ) - Multiple sclerosis: treatment safety
doc. MUDr. Martin Vališ, Ph.D., MUDr. Zbyšek Pavelek
(5/2018, Review articles ) - Fingolimod treatment of multiple sclerosis at any age
doc. MUDr. Radomír Taláb, CSc., MUDr. Marika Talábová
(2/2022, Review articles ) - NEDA-4 concept as a treatment outcome in multiple sclerosis patients
MUDr. Pavel Hradílek, Ph.D.
(3/2016, Review articles ) - High-efficacy drugs in early stage of multiple sclerosis
MUDr. Veronika Tichá, Ph.D.
(5/2022, Review articles ) - Monoklonální protilátky v léčbě roztroušené sklerózy
MUDr. Marek Peterka , MUDr. Zdeněk Kasl, Ph.D.
(2/2018, Pharmacotherapy ) - Biological therapy by Ocrelizumab (antiCD20) is surprisingly clinically effective in multiple sclerosis patients
Prof. RNDr. Jan Krejsek, CSc.
(6/2017, From the boundary of neurology ) - A battle for grey matter: is Ocrelizumab gaining an advantage?
MUDr. Simona Halúsková, Ph.D., MBA, MUDr. Miroslav Mareš, MUDr. Alena Martinková, MUDr. Linda Bláhová, MUDr. Věra Křivková, MUDr. Marek Klíma
(2/2026, Trends in neuropharmacotherapy ) - Anti-CD20 therapy in relapsing-remitting multiple sclerosis: long term ofatumumab data in treatment naive patients
MUDr. Martin Karlík, PhD.
(2/2026, Information & comments ) - Long-term data of multiple sclerosis treatment with ocrelizumab – eficacy, safety and clinical experience
MUDr. Mgr. Matouš Rous, MUDr. Zuzana Rous, Ph.D.
(6/2021, Review articles ) - Treatment of multiple sclerosis in Czech Republic – options and reality
MUDr. Michal Dufek
(1/2014, Review articles ) - Ocrelizumab – what we know, what we can improve now, what we can improve in the future
MUDr. Martin Elišák, Ph.D.
(1/2024, Review articles ) - Ofatumumab in clinical practice
MUDr. Martin Elišák, Ph.D.
(1/2024, Review articles ) - Neurofilament light chain and disease activity in patients with multiple sclerosis
doc. MUDr. Jarmila Szilasiová, PhD., MUDr. Miriam Fedičová
(3/2021, Review articles ) - Treatment persistence to ocrelizumab and local experience
MUDr. Simona Halúsková, prof. MUDr. Martin Vališ, Ph.D., FEAN
(3/2021, Review articles ) - Efficacy and safety of ofatumumab in naive MS patients.
MUDr. Martina Martiníková
(5/2023, Informations ) - Ocrelizumab is dampening the harm inflammation in patients with multiple sclerosis with little impact on protective immunity
prof. RNDr. Jan Krejsek, CSc.
(3/2020, From the boundary of neurology ) - Ocrelizumab and treatment of multiple sclerosis during pregnancy and breastfeeding
MUDr. Jana Pavlíčková, Ph.D.
(6/2025, Trends in neuropharmacotherapy ) - B lymfocyty v roztroušené skleróze mozkomíšní a postavení biologika cílícího na B lymfocyty v její léčbě
prof. RNDr. Jan Krejsek, CSc.
(3/2018, From the boundary of neurology ) - B cells as a target in the treatment of multiple sclerosis
MUDr. Luděk Hochmuth
(3/2017, Review articles ) - Continuous immunomodulation and immunosuppression versus reconstitution therapy in multiple sclerosis
doc. MUDr. Ema Kantorová, PhD.
(3/2025, Main topic ) - Evaluating the efficacy of treatment for multiple sclerosis in the practice; development of the NEDA concept
prof. MUDr. Eva Kubala Havrdová, DrSc.
(3/2025, Main topic ) - IAT + AHSCT: role of high-dose immunoablative therapy with autologous haematopoietic stem cell transplantation in patients with multiple sclerosis
doc. MUDr. Pavel Hradílek, Ph.D.
(3/2025, Main topic ) - The impact of immunosupressive therapy on the immune system of a patient with multiple sclerosis
prof. MUDr. Mgr. Miloš Jeseňák, PhD., MBA, MHA, Dott.Ric., FAAAAI, prof. MUDr. Jarmila Szilasiová, PhD.
(3/2025, Main topic ) - Multiple sclerosis – maternity and breastfeeding
MUDr. Olga Zapletalová
(1/2019, Review articles ) - Ocrelizumab – long-term efficacy and safety in real-world clinical practice in patients with relapsingremitting multiple sclerosis
MUDr. Martin Elišák, Ph.D.
(3/2022, Review articles ) - New perspective treatment of multiple sclerosis
doc. MUDr. Vladimír Donáth, CSc., MUDr. Silvia Laurincová
(2/2014, Main topic ) - Ocrelizumab, clinical aktivity and progression – long-term data
MUDr. Zbyšek Pavelek, PhD., doc. MUDr. Martin Vališ, Ph.D.
(3/2019, Pharmacotherapy ) - Immunosuppressive treatment of multiple sclerosis and risk (of reactivation) of viral hepatitides
MUDr. Václav Hejda, MUDr. Aleš Tvaroh, Ph.D.
(4/2020, From the boundary of neurology ) - Longterm safety of Ocrelizumab in Multiple Sclerosis treatment
MUDr. Marek Peterka , MUDr. Pavel Potužník
(4/2020, Review articles ) - Multiple sclerosis and pregnancy – first line treatment and escalation therapy
MUDr. Simona Halúsková, doc. MUDr. Martin Vališ, Ph.D.
(6/2019, Review articles ) - B-cell targeted therapy to impact the progression of multiple sclerosis
MUDr. Martin Elišák, Ph.D.
(3/2023, Review articles ) - Long-term efficacy and safety of ofatumumab in the treatment of multiple sclerosis
MUDr. Marek Peterka
(6/2022, Review articles ) - MS and NMOSD during the pandemic COVID-19 – what have we already learnt?
MUDr. Dominika Šťastná, MUDr. Ingrid Menkyová, doc. MUDr. Dana Horáková, Ph.D.
(4/2021, Review articles ) - Biologics targeting CD20 molecule on B cells in the therapy of multiple sclerosis patients
Prof. RNDr. Jan Krejsek, CSc.
(6/2022, From the boundary of neurology ) - Shorter infusion of ocrelizumab in the treatment of multiple sclerosis
MUDr. Marek Peterka , MUDr. Pavel Potužník
(4/2021, Review articles ) - MR monitoring of activity of multiple sclerosis patients: conventional techniques and long-term MR monitoring of ocrelizumab therapy
prof. MUDr. Manuela Vaněčková, Ph.D.
(6/2019, From the boundary of neurology ) - Cortical inflammation in pathogenesis of multiple sclerosis
doc. MUDr. Vladimír Donáth, PhD.
(4/2019, Review articles ) - Significance of multiple sclerosis early treatment
doc. MUDr. Ema Kantorová, PhD.
(4/2019, Review articles ) - Ocrelizumab v léčbě roztroušené sklerózy
Prof. MUDr. Eva Kubala Havrdová, CSc.
(4/2017, Pharmacotherapy ) - Neurofilament light chain (NfL) and glial fibrillary acid protein (GFAP) as biomarkers disease activity and therapeutic response in multiple sclerosis treated with ocrelizumab
prof. MUDr. Pavel Štourač, Ph.D.
(3/2026, Trends in neuropharmacotherapy ) - B‑ lymphocyte‑ targeted MS therapy: from theory to a decade of ocrelizumab in practice
MUDr. Dominika Šťastná, Ph.D., MUDr. Jana Seňavová, prof. MUDr. Dana Horáková, Ph.D.
(2/2024, Review articles ) - The influence on long-term progression of multiple sclerosis – brighter days ahead?
MUDr. Dominika Šťastná, doc. MUDr. Dana Horáková, Ph.D.
(1/2021, Review articles ) - Does the development of new drugs for multiple sclerosis change the prognosis of the patient?
prof. MUDr. Eva Havrdová, CSc.
(3/2011, Review articles ) - The new trends in multiple sclerosis treatment
prof. MUDr. Ľubomír Lisý, DrSc.
(2/2020, Review articles ) - Tailored MS care: ocrelizumab among the pioneers of exposure-based treatment?
MUDr. Dominika Šťastná, Ph.D.
(4/2025, Trends in neuropharmacotherapy ) - Ocrelizumab and novel therapeutic goals in multiple sclerosis
MUDr. Radek Ampapa
(2/2020, Review articles )
- New trends in MS treatment in children
MUDr. Jana Surgošová
(2/2022, Review articles )
- New therapy options for multiple sclerosis
Mgr. Ivana Pankuchová, MUDr. Ľubica Procházková, CSc., PharmDr. Adela Čorejová, PhD.
(4/2013, Current pharmacotherapy )